ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

In a draft assessment, the non-profit said Madrigal’s non-alcoholic steatohepatitis candidate might yield cost savings over a lifetime of care. Both drugs seem to offer incremental benefits for survival and quality of life.